Talzenna .25 mg/1

Talzenna .25 mg/1 is a liquid-filled capsule containing talazoparib, used for targeted therapy. This medication is designed for oral administration and is available in a 30-capsule bottle.

Talzenna .25 mg/1 is primarily used in the treatment of certain types of cancer. Talazoparib is a PARP inhibitor, which works by targeting specific enzymes involved in DNA repair. This medication is often prescribed for patients with specific genetic mutations that affect DNA repair mechanisms. What is Talzenna used for? It is typically used in the management of advanced or metastatic cancers, particularly those associated with BRCA mutations.

Common effects of Talzenna .25 mg/1 may include fatigue, nausea, and anemia. Some patients may experience vomiting, diarrhea, or a decrease in appetite. It is important to monitor for any unusual symptoms and consult a healthcare provider if severe side effects occur.

Talzenna .25 mg/1 should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting this medication. Pregnant or breastfeeding women should discuss the potential risks with their healthcare provider.

Talzenna .25 mg/1 may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking. Alcohol and other substances that affect liver function should be avoided unless approved by a healthcare provider.